NEWS

August 22, 2022
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 17, 2022
Travere Therapeutics Named Finalist for the 2022 PM360 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year Award
August 11, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 9, 2022
Travere Therapeutics Named 2022 Bronze Winner of The Stevie Awards for Great Employers
August 4, 2022
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Travere Therapeutics Provides Regulatory Updates on its Development Programs
July 28, 2022
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 12, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2022
Eric Dube Named EY Entrepreneur of the Year 2022 Pacific Southwest Award Winner
June 14, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2022
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
May 17, 2022
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress